These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33279177)

  • 1. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
    Swoboda DM; Sallman DA
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies.
    Chao MP; Takimoto CH; Feng DD; McKenna K; Gip P; Liu J; Volkmer JP; Weissman IL; Majeti R
    Front Oncol; 2019; 9():1380. PubMed ID: 32038992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Abaza Y; Zeidan AM
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective.
    Chen YC; Shi W; Shi JJ; Lu JJ
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):1-14. PubMed ID: 34609596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies.
    Wang C; Sallman DA
    Curr Opin Hematol; 2022 Jan; 29(1):44-52. PubMed ID: 34854834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy.
    Li Z; Li Y; Gao J; Fu Y; Hua P; Jing Y; Cai M; Wang H; Tong T
    Life Sci; 2021 May; 273():119150. PubMed ID: 33662426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
    Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
    Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
    Voets E; Paradé M; Lutje Hulsik D; Spijkers S; Janssen W; Rens J; Reinieren-Beeren I; van den Tillaart G; van Duijnhoven S; Driessen L; Habraken M; van Zandvoort P; Kreijtz J; Vink P; van Elsas A; van Eenennaam H
    J Immunother Cancer; 2019 Dec; 7(1):340. PubMed ID: 31801627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
    Bewersdorf JP; Zeidan AM
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101222. PubMed ID: 33279182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes.
    Gallazzi M; Ucciero MAM; Faraci DG; Mahmoud AM; Al Essa W; Gaidano G; Mouhssine S; Crisà E
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
    Venugopal S; Daver N; Ravandi F
    Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
    Zeidan AM; DeAngelo DJ; Palmer J; Seet CS; Tallman MS; Wei X; Raymon H; Sriraman P; Kopytek S; Bewersdorf JP; Burgess MR; Hege K; Stock W
    Ann Hematol; 2022 Mar; 101(3):557-569. PubMed ID: 34981142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.